RxDoctor Payments Data

Rachel Allen

Physician Assistant · Amherst, NYNPI 1134668908

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $35,070 of the $53,947 with a category attached, or 65.0%. AbbVie accounts for 72.2% of it on its own, with 59 other manufacturers making up the rest. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,947in general payments, 2019–2025

Across 1,064 payments — averaging $50.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • Amgen$2K
  • UCB, Inc.$2K
  • MDD US Operations, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$873
  • Biohaven Pharmaceuticals, Inc.$628
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$7881%
  • Speaking & faculty fees$35,07065%
  • Travel & lodging$7481%
  • Food & beverage$17,15032%
  • Education$1900%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)205$38,966
Amgen121$2,216
UCB, Inc.73$1,530
MDD US Operations, LLC41$1,307
Teva Pharmaceuticals USA, Inc.43$873
Biohaven Pharmaceuticals, Inc.65$628
Tonix Medicines, Inc.52$616
Impel Pharmaceuticals Inc.30$422
AstraZeneca(2 entities)20$401
Neurelis, Inc.22$390
Amneal Pharmaceuticals LLC39$385
Lundbeck LLC23$363
Neurocrine Biosciences, Inc.20$359
Livanova USA, Inc.8$358
Avanir Pharmaceuticals, Inc.16$343
Lilly USA, LLC20$327
Axsome Therapeutics, Inc.15$305
Upsher-smith Laboratories LLC18$294
Catalyst Pharmaceuticals, Inc.12$275
Currax Pharmaceuticals LLC18$247
Jazz Pharmaceuticals Inc.10$219
Kyowa Kirin, Inc.12$217
Pfizer13$209
Johnson & Johnson5$175
Biohaven Pharmaceutical Holding Company Ltd.36$165
CSL Behring7$160
Acadia Pharmaceuticals Inc9$148
Impel Pharmaceuticals LLC6$144
Supernus Pharmaceuticals, Inc.8$134
Abbott7$131
Azurity Pharmaceuticals, Inc.7$128
SK Life Science, Inc.5$127
Otsuka America Pharmaceutical, Inc.6$112
Scilex Pharmaceuticals Inc.7$110
Grifols USA, LLC5$103
Tanabe Pharma America, Inc.6$102
Adamas Pharmaceuticals, Inc.4$87
Ipsen Biopharmaceuticals, Inc4$74
Eisai Inc.3$69
Banner Life Sciences, LLC4$67
Novartis4$65
Xeris Pharmaceuticals, Inc.3$60
Averitas Pharma Inc.3$58
Octapharma USA, Inc.3$51
GE HealthCare4$44
Almatica Pharma LLC3$44
Harmony Biosciences LLC2$43
Akcea Therapeutics, Inc.2$42
Takeda Pharmaceuticals U.S.A., Inc.2$37
Nobelpharma America, LLC2$36
Arbor Pharmaceuticals, Inc.2$32
Sobi, Inc1$21
Sanofi1$21
Merz Pharmaceuticals, LLC1$19
Vanda Pharmaceuticals Inc.1$19
Biogen1$18
Alnylam Pharmaceuticals Inc.1$16
Amylyx Pharmaceuticals, Inc.1$14
Corium, LLC1$14
Collegium Pharmaceutical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,947 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$57,547
Medicare patients
52
Services billed
7,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant75$93,643
Nurtec OdtRimegepant Sulfate65$85,640
Emgality PenGalcanezumab-Gnlm82$63,603
UbrelvyUbrogepant50$61,921
Ajovy AutoinjectorFremanezumab-Vfrm52$48,621
Aimovig AutoinjectorErenumab-Aooe34$28,039
Ajovy SyringeFremanezumab-Vfrm22$16,676
Emgality SyringeGalcanezumab-Gnlm14$15,145
Topiramate ErTopiramate36$13,212
Sumatriptan Succinate157$11,603
Diclofenac Potassium11$4,165
Divalproex Sodium21$1,982
Topiramate114$1,242
RizatriptanRizatriptan Benzoate75$921
Acetazolamide13$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$38,966$155,564125 claims
PfizerNurtec Odt$209$85,64065 claims
Upsher-smith Laboratories LLCTopiramate$294$1,242114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →